Develops antibody drug candidates using artificial intelligence to treat obesity and related metabolic and heart-lung diseases.
10-K for FY2026, filed Aug 28, 2026iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power…View ↗
Obesity is associated with a broad range of cardiometabolic and cardiopulmonary complications, therefore, we are also evaluating selected…View ↗
Following Clinical Trial Notification (“CTN”) acknowledgement from Australia’s Therapeutic Goods Administration (“TGA”) and ethics approval…View ↗
It charges a fixed amount for a project deliverable, typically after completion and delivery; research collaborations may also bring milestone payments tied to future development events.
10-K for FY2026, filed Aug 28, 2026
$100K
10-K for FY2026, filed Aug 28, 2026
$100K ↗
Works with research collaborators on antibody programs; it also seeks partners for selected drug candidates and for use of its discovery and screening technologies.
10-K for FY2026, filed Aug 28, 2026Expanded the amylin receptor antibody program we are working with in collaboration with AstralBio by combining new GPCR antigen engineering…View ↗
Developing and Advancing our Pipeline Cost Effectively: Drug discovery and clinical advancement of our pipeline remain central to our…View ↗
Out-Licensing in Diverse Therapeutic Areas: We are evaluating opportunities for out-licensing our AI Drug Discovery Platform to broaden its…View ↗
No. It lost $33M in FY2026.
Shrinking. Revenue fell 95% in 4 years, from $1.9M in FY2022 to $100K in FY2026, about 52% a year.
Therapeutic focus
The earlier report focused its in-house programs on oncology; the latest report centers on antibody medicines for obesity and related metabolic and heart-lung diseases.
10-K for FY2023, filed Sep 27, 2023 10-K for FY2026, filed Aug 28, 2026Developing and advancing our in-house programs cost effectively: Clinical advancement is crucial for drug discovery. We are actively…View ↗
Competes with Eli Lilly, Novo Nordisk, Amgen, Bristol-Myers Squibb, Merck &, Novartis, MedImmune, Johnson & Johnson, Pfizer, Merck, Sanofi, Genentech, Regeneron, Keros Therapeutics, Scholar Rock, Biohaven, Basecure Therapeutics, Structure Therapeutics, Viking Therapeutics, and Veru
10-K for FY2026, filed Aug 28, 2026As a biopharmaceutical company developing next generation obesity therapeutics, we compete with a broad range of companies. At the highest…View ↗
Loading...